The Role of PI3K Inhibition in the Treatment of Breast Cancer, Alone or Combined With Immune Checkpoint Inhibitors

被引：37

作者：

Zhang, Zhizhu ^{[1
]}

Richmond, Ann ^{[2
,3
]}

机构：

[1] Vanderbilt Univ, Dept Biol Sci, 221 Kirkland Hall, Nashville, TN 37235 USA

[2] Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37235 USA

[3] Tennessee Valley Healthcare Syst, Dept Vet Affairs, Nashville, TN 37212 USA

来源：

FRONTIERS IN MOLECULAR BIOSCIENCES | 2021年 / 8卷

关键词：

PI3K inhibition; breast cancer; immune checkpoint inhibitors; MDSC; tumor immune microenvironment; PHOSPHATIDYLINOSITOL; 3-KINASE; TUMOR-SUPPRESSOR; BLOCKADE THERAPY; DOUBLE-BLIND; PHASE-I; RESISTANCE; TRASTUZUMAB; PI3K-GAMMA; PI3K/MTOR; CHEMOTHERAPY;

D O I：

10.3389/fmolb.2021.648663

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Dysregulation of phosphoinositide 3-kinase (PI3K) signaling is highly implicated in tumorigenesis, disease progression, and the development of resistance to the current standard of care treatments in breast cancer patients. This review discusses the role of PI3K pathway in breast cancer and evaluates the clinical development of PI3K inhibitors in both early and metastatic breast cancer settings. Further, this review examines the evidence for the potential synergistic benefit for the combination treatment of PI3K inhibition and immunotherapy in breast cancer treatment.

引用

页数：10

共 68 条

[1] Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by Ex Vivo PI3K-δ Inhibition [J].

Abu Eid, Rasha ;

Ahmad, Shamim ;

Lin, Yuan ;

Webb, Mason ;

Berrong, Zuzana ;

Shrimali, Rajeev ;

Kumai, Takumi ;

Ananth, Sudha ;

Rodriguez, Paulo C. ;

Celis, Esteban ;

Janik, John ;

Mkrtichyan, Mikayel ;

Khleif, Samir N. .

CANCER RESEARCH, 2017, 77 (15) :4135-4145

[2] Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B alpha [J].

Alessi, DR ;

James, SR ;

Downes, CP ;

Holmes, AB ;

Gaffney, PRJ ;

Reese, CB ;

Cohen, P .

CURRENT BIOLOGY, 1997, 7 (04) :261-269

[3] Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer [J].

Ali, Khaled ;

Soond, Dalya R. ;

Pineiro, Roberto ;

Hagemann, Thorsten ;

Pearce, Wayne ;

Lim, Ee Lyn ;

Bouabe, Hicham ;

Scudamore, Cheryl L. ;

Hancox, Timothy ;

Maecker, Heather ;

Friedman, Lori ;

Turner, Martin ;

Okkenhaug, Klaus ;

Vanhaesebroeck, Bart .

NATURE, 2014, 510 (7505) :407-+

[4] Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer [J].

Andre, Fabrice ;

Ciruelos, Eva ;

Rubovszky, Gabor ;

Campone, Mario ;

Loibl, Sibylle ;

Rugo, Hope S. ;

Iwata, Hiroji ;

Conte, Pierfranco ;

Mayer, Ingrid A. ;

Kaufman, Bella ;

Yamashita, Toshinari ;

Lu, Yen-Shen ;

Inoue, Kenichi ;

Takahashi, Masato ;

Papai, Zsuzsanna ;

Longin, Anne-Sophie ;

Mills, David ;

Wilke, Celine ;

Hirawat, Samit ;

Juric, Dejan .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (20) :1929-1940

[5] Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER. [J].

Baselga, Jose ;

Dent, Susan Faye ;

Cortes, Javier ;

Im, Young-Hyuck ;

Dieras, Veronique ;

Harbeck, Nadia ;

Krop, Ian E. ;

Verma, Sunil ;

Wilson, Timothy R. ;

Jin, Huan ;

Wang, Lijia ;

Schimmoller, Frauke ;

Hsu, Jerry Y. ;

He, Jing ;

DeLaurentiis, Michelino ;

Drullinsky, Pamela ;

Jacot, William .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (18)

[6] Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Baselga, Jose ;

Im, Seock-Ah ;

Iwata, Hiroji ;

Cortes, Javier ;

De laurentiis, Michele ;

Jiang, Zefei ;

Arteaga, Carlos L. ;

Jonat, Walter ;

Clemons, Mark ;

Ito, Yoshinori ;

Awada, Ahmad ;

Chia, Stephen ;

Jagiello-Gruszfeld, Agnieszka ;

Pistilli, Barbara ;

Tseng, Ling-Ming ;

Hurvitz, Sara ;

Masuda, Norikazu ;

Takahashi, Masato ;

Vuylsteke, Peter ;

Hachemi, Soulef ;

Dharan, Bharani ;

Di Tomaso, Emmanuelle ;

Urban, Patrick ;

Massacesi, Cristian ;

Campone, Mario .

LANCET ONCOLOGY, 2017, 18 (07) :904-916

[7]

Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]

[8] International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy [J].

Cardoso, Fatima ;

Bedard, Philippe L. ;

Winer, Eric P. ;

Pagani, Olivia ;

Senkus-Konefka, Elzbieta ;

Fallowfield, Lesley J. ;

Kyriakides, Stella ;

Costa, Alberto ;

Cufer, Tanja ;

Albain, Kathy S. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (17) :1174-1181

[9]

Castellano Esther, 2011, Genes Cancer, V2, P261, DOI 10.1177/1947601911408079

[10] Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic [J].

Chan, T. A. ;

Yarchoan, M. ;

Jaffee, E. ;

Swanton, C. ;

Quezada, S. A. ;

Stenzinger, A. ;

Peters, S. .

ANNALS OF ONCOLOGY, 2019, 30 (01) :44-56

← 1 2 3 4 5 6 7 →